KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Other Non-Current Liabilities: 2010-2024

Historic Other Non-Current Liabilities for Pacira BioSciences (PCRX) over the last 15 years, with Dec 2024 value amounting to $20.2 million.

  • Pacira BioSciences' Other Non-Current Liabilities rose 32.09% to $25.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.3 million, marking a year-over-year increase of 32.09%. This contributed to the annual value of $20.2 million for FY2024, which is 18.05% down from last year.
  • Pacira BioSciences' Other Non-Current Liabilities amounted to $20.2 million in FY2024, which was down 18.05% from $24.7 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Other Non-Current Liabilities registered a high of $57.6 million during FY2021, and its lowest value of $13.6 million during FY2020.
  • Its 3-year average for Other Non-Current Liabilities is $24.4 million, with a median of $24.7 million in 2023.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 323.20% in 2021, then crashed by 51.18% in 2022.
  • Yearly analysis of 5 years shows Pacira BioSciences' Other Non-Current Liabilities stood at $13.6 million in 2020, then surged by 323.20% to $57.6 million in 2021, then tumbled by 51.18% to $28.1 million in 2022, then declined by 12.18% to $24.7 million in 2023, then declined by 18.05% to $20.2 million in 2024.